Novel peroxisome proliferator-activated receptor ligands for Type 2 diabetes and the metabolic syndrome

被引：30

作者：

Miller, AR ^{[1
]}

Etgen, GJ ^{[1
]}

机构：

[1] Eli Lilly & Co, Lilly Res Labs, Div Endocrine, Indianapolis, IN 46285 USA

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2003年 / 12卷 / 09期

关键词：

diabetes; PPAP; syndrome X; TZD;

D O I：

10.1517/eoid.12.9.1489.21821

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

As the incidence of Type 2 diabetes has reached near epidemic proportions, the quest for novel therapies; to combat this disorder has intensified dramatically. In recent years, the peroxisome proliferator-activated receptor (PPAR) family has received tremendous attention as perhaps an ideal target class to address the multiple metabolic anomalies associated with the diabetic state. This review focuses on a variety of novel PPAR approaches currently being investigated for Type 2 diabetes or the metabolic syndrome, including the highly potent selective PPAR agonists, PPAR combination agonists and alternative PPAR ligands.

引用

页码：1489 / 1500

页数：12

共 99 条

[41] Activation of specific RXR heterodimers by an antagonist of RXR homodimers [J].

Lala, DS ;

Mukherjee, R ;

Schulman, IG ;

Koch, SSC ;

Dardashti, LJ ;

Nadzan, AM ;

Croston, GE ;

Evans, RM ;

Heyman, RA .

NATURE, 1996, 383 (6599) :450-453

[42] Rosiglitazone monotherapy is effective in patients with type 2 diabetes [J].

Lebovitz, HE ;

Dole, JF ;

Patwardhan, R ;

Rappaport, EB ;

Freed, MI .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (01) :280-288

[43] Activation of PPARδ alters lipid metabolism in db/db mice [J].

Leibowitz, MD ;

Fiévet, C ;

Hennuyer, N ;

Peinado-Onsurbe, J ;

Duez, H ;

Berger, J ;

Cullinan, CA ;

Sparrow, CP ;

Baffic, J ;

Berger, GD ;

Santini, C ;

Marquis, RW ;

Tolman, RL ;

Smith, RG ;

Moller, DE ;

Auwerx, J .

FEBS LETTERS, 2000, 473 (03) :333-336

[44] Identification of a series of PPAR-γ/δ dual agonists via solid-phase parallel synthesis [J].

Liu, KG ;

Lambert, MH ;

Leesnitzer, LM ;

Oliver, W ;

Ott, RJ ;

Plunket, KD ;

Stuart, LW ;

Brown, PJ ;

Willson, TM ;

Sternbach, DD .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (22) :2959-2962

[45] Cervical cancer in Canada: Changing patterns in incidence and mortality [J].

Liu, S ;

Semenciw, R ;

Probert, A ;

Mao, Y .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2001, 11 (01) :24-31

[46] (-)3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: A dual PPAR agonist with potent antihyperglycemic and lipid modulating activity [J].

Lohray, BB ;

Lohray, VB ;

Bajji, AC ;

Kalchar, S ;

Poondra, RR ;

Padakanti, S ;

Chakrabarti, R ;

Vikramadithyan, RK ;

Misra, P ;

Juluri, S ;

Mamidi, NVSR ;

Rajagopalan, R .

JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (16) :2675-2678

[47] Novel euglycemic and hypolipidemic agents. 1 [J].

Lohray, BB ;

Bhusan, V ;

Rao, BP ;

Medhavan, GR ;

Murali, N ;

Rao, KN ;

Reddy, AK ;

Rajesh, BM ;

Reddy, PG ;

Chakrabarti, R ;

Vikramadithyan, RK ;

Rajagopalan, R ;

Mamidi, RNVS ;

Jajoo, HK ;

Subramanian, S .

JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (10) :1619-1630

[48] Novel indole containing thiazolidinedione derivatives as potent euglycemic and hypolipidaemic agents [J].

Lohray, BB ;

Bhushan, V ;

Rao, PB ;

Madhavan, GR ;

Murali, N ;

Rao, KN ;

Reddy, KA ;

Rajesh, BM ;

Reddy, PG ;

Chakrabarti, R ;

Rajagopalan, R .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (07) :785-788

[49] Metabolic and additional vascular effects of thiazolidinediones [J].

Martens, FMAC ;

Visseren, FLJ ;

Lemay, J ;

de Koning, EJP ;

Rabelink, TJ .

DRUGS, 2002, 62 (10) :1463-1480

[50] ANALYSIS OF ESTROGEN-RECEPTOR FUNCTION IN-VITRO REVEALS 3 DISTINCT CLASSES OF ANTIESTROGENS [J].

MCDONNELL, DP ;

CLEMM, DL ;

HERMANN, T ;

GOLDMAN, ME ;

PIKE, JW .

MOLECULAR ENDOCRINOLOGY, 1995, 9 (06) :659-669

← 1 2 3 4 5 6 7 8 9 10 →